Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Ligand Pharma (LGND) Tops Q4 EPS by 17c
February 21, 2018 4:02 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $50.5 million versus the consensus estimate of $47.82 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
... More